Big Pharma Lukewarm To License Compounds From Indian Start-ups, But A Few Could Be Head Turners
This article was originally published in PharmAsia News
MUMBAI - Faced with the bleak prospect of an almost irreversible pipeline drought, Big Pharma has sharpened its focus on identifying differentiated leads from smaller firms - mainly to in-license early-stage compounds - but it appears there are few Indian start-ups with compounds that fit into this strategic goal
You may also be interested in...
MUMBAI - One of the top priorities for U.S. President Barack Obama during his four day visit to India may be to seek strengthened IP rights protection from the Indian government - a thorny issue that has kept some multinational companies away from committing R&D investments in the country despite availability of a large pool of scientists and significant cost advantages
Prime Minister's Intervention On Patents And Data Protection Issue Sparks Fresh Row Between Indian And Multinational Drug Makers
MUMBAI - Leading multinational and India drug companies are heading for a veritable face-off over a decision of the prime minister's office to step in for a comprehensive legislative review of contentious statutes related to patent law in India
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).